Why Acadia Pharmaceuticals ( ACAD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Acadia ( ACAD ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Catherine Owen AdamsContinue reading ...
Acadia Pharmaceuticals ( ACAD ) Q3 Earnings and Revenues Top Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +85.71% and +1.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Waters Q3 Earnings Surpass Estimates, Revenue Increase Y/Y
WAT posts strong Q3 results with 16% earnings growth and higher sales, lifting its full-year outlook for 2025.
Analysts Estimate Acadia Pharmaceuticals ( ACAD ) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia ( ACAD ) Moves to Buy: Rationale Behind the Upgrade
Acadia (ACAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Acadia ( ACAD ) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?
The mean of analysts' price targets for Acadia (ACAD) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is HCA HEALTHCARE ( HCA ) Stock Outpacing Its Medical Peers This Year?
Here is how HCA Healthcare (HCA) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Hims & Hers Health ( NYSE:HIMS ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
Boston, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Anti-Parkinson's Drugs: Global Markets to 2030" is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 8.6% from 2025 to 2030.
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen ( QGEN Quick QuoteQGEN - ) and Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .
ACADIA Pharmaceuticals EVP Trades $82K In Company Stock - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Mark Schneyer, EVP at ACADIA Pharmaceuticals ACAD, reported an insider sell on September 16, according to a new SEC filing. What Happened: Schneyer's decision to sell 3,498 shares of ACADIA Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday.
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia ( ACAD ) Q2 Revenue Rises 9%
Acadia Pharmaceuticals ( NASDAQ:ACAD ) , a neuroscience-focused biopharma company behind treatments for central nervous system diseases, reported its earnings for Q2 2025 on August 6, 2025. The most notable news was a slight beat on both GAAP earnings and revenue, driven by ongoing growth in its ...
Acadia Pharmaceuticals ( ACAD ) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies ( ADPT ) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR ( GMAB Quick QuoteGMAB - ) and Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks offers value investors a better bang for their buck right ...
Acadia Pharmaceuticals ( ACAD ) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
KMDA or ACAD: Which Is the Better Value Stock Right Now?
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada ( KMDA Quick QuoteKMDA - ) or Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look ...
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Court ruling secures Nuplazid's 34 mg formulation patent protection through 2038. JPMorgan hikes Acadia target from $26 to $30, citing strong patent outlook. Get access to the leaderboards pointing to tomorrow's biggest stock movers. In May, the U.S.
Why Is Acadia ( ACAD ) Up 26.1% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK or ACAD: Which Is the Better Value Stock Right Now?
GSK vs. ACAD: Which Stock Is the Better Value Option?
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday. The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's '721 formulation patent for NUPLAZID ( pimavanserin ) , a treatment for Parkinson's Disease Psychosis.
Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Archer-Daniels-Midland ( NYSE:ADM ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised ACADIA Pharmaceuticals Inc. ACAD price target from $27 to $30.
Acadia Pharmaceuticals ( ACAD ) Stock Explodes 26% After Patent Court Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.
Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Archer Aviation ( NYSE:ACHR ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session after the company announced preliminary first-quarter financial results. The company said it expects revenue growth of 40%+ in the ...
Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates ( Revised )
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
